AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05363423 — intervention group
Intervention type: PROCEDURE
Intervention: Draf III procedure with lateral pedicled nasoseptal flaps applied
Description: The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table.
Study NCT05363423 — intervention group
Intervention type: PROCEDURE
Intervention: Draf III procedure without any flap applied
Description: The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre.
Study NCT05073874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional Near-Infrared Spectroscopy (fNIRS)
Description: The hemodynamic response in prefrontal cortex will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
Study NCT06294106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)
Description: EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.
Study NCT06294106 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroencephalogram personalized Transcranial Magnetic Stimulation (eTMS)
Description: EEG is utilized to determine a personalized frequency to then apply TMS to the frontal lobe.
Study NCT04725578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Single Session Consultation
Description: A remotely delivered, single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
Study NCT04740008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Nicotine Content Cigarettes
Description: Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes
Study NCT04740008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control message
Description: Participants will read control message
Study NCT04740008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test message
Description: Participants will read test message
Study NCT06236269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan 10 mg/kg will be administrad intravenously (IV) on Days 1, 8 of a 21-day cycle
Study NCT03826303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette liquid with ethanol, 1 puff
Description: E-cigarette liquid with ethanol, 1 puff
Study NCT03826303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-cigarette liquid without ethanol, 1 puff
Description: E-cigarette liquid without ethanol, 1 puff
Study NCT03826303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette liquid with ethanol, 10 puffs
Description: E-cigarette liquid with ethanol, 10 puffs
Study NCT03826303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-cigarette liquid without ethanol, 10 puffs
Description: E-cigarette liquid without ethanol, 10 puffs
Study NCT04976400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: semi-individualized total knee replacement treatment with a gender-specific design
Description: Patients in the experimental group received a semi-individualized total knee replacement treatment with a gender-specific design.
Study NCT04976400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA)
Description: Patients in the control group received imported Zimmer total knee replacement prostheses (Zimmer, Warsaw, IN, USA).
Study NCT04682366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral drug: 10 days of 0.4 mg of oral Tamsulosin
Study NCT04682366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drug: 10 days of identical-appearing placebo
Study NCT05694754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
Study NCT06023082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colon Broom Premium supplement
Description: The product contains the following ingredients:~Psyllium Seed Husk Powder L-Carnitine Tartrate Capsimax® Cayenne Fruit Extract Chromium (as Chromium Picolinate) Vitamin B6 (as Pyridoxine HCl) Vitamin B12 (as Cyanocobalamin) Iron
Study NCT06096896 — intervention group
Intervention type: PROCEDURE
Intervention: MWA
Description: Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
Study NCT06190678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally
Study NCT04751708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular treatment
Description: For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
Study NCT04751708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical management
Description: best medical management
Study NCT06524752 — intervention group
Intervention type: OTHER
Intervention: The presence of nausea and vomiting within 24 hours after surgery
Description: This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
Study NCT06524752 — intervention group
Intervention type: OTHER
Intervention: Non-existence of nausea and vomiting within 24 hours after surgery
Description: This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
Study NCT04921137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No endocrine therapy
Description: No endocrine therapy given
Study NCT04921137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Endocrine therapy given for at least 5 years
Study NCT04994288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Supaglutide injection
Description: Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml
Study NCT04994288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: placebo injection 0.5ml
Study NCT05679752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial PNF technique
Description: Stimulation techniques used to facilitate the weak muscle groups
Study NCT05679752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: frictional massage to stimulate the weak muscle groups
Study NCT03616041 — intervention group
Intervention type: DEVICE
Intervention: Second-generation colon capsule endoscopy system
Description: The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
Study NCT05021406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 MG
Description: Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.
Study NCT04098718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: 100mg sub cut once only
Study NCT04098718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 30mg tablet daily for 5 days
Study NCT04098718 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: 30mg tablet daily for 5 days
Study NCT04098718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 30mg tablet daily for 5 days
Study NCT04846738 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Doppler
Description: This device measures Mean Systolic Velocity (VMS), Tele-Diastolic Velocity (TDV) and Pulsatility Index (PI),
Study NCT04846738 — intervention group
Intervention type: DEVICE
Intervention: Pupillometry.
Description: This device measures the photomotor reflex (basic pupil diameter, percentage of variation, latent and slope of the standard photomotor reflex)
Study NCT04907136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred ENDS
Description: Preferred ENDS without HWL on device
Study NCT05831930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nituozumab
Description: Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
Study NCT04708756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collabree Mobile Phone Application Medication Adherence Booster (simplified version)
Description: Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
Study NCT04708756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collabree Mobile Phone Application Medication Adherence Booster
Description: Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
Study NCT04907136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred ENDS with HWL
Description: Preferred ENDS with a HWL on device
Study NCT04690049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular resistance exercise program
Description: This neuromuscular resistance exercise program will be organized in 5 stages, distributing the different phases in 2, 4, 4, 2 and 2 weeks respectively, with a frequency of 3 sessions/week. In addition, 2 weekly sessions of aerobic work with cycloergometer will be developed. The duration of each session will last 30 minutes. The parameters of load and execution speed will be modified as the exercise program progresses along the phases, with the goal of have an impact on the different aspects of the neuromuscular system.
Study NCT04690049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control exercise program with elastic band
Description: This program is based on previous literature so that it remains comparable to the experimental program.~The parameters will consist in 3 sets of 10 repetitions, 2 times/day, 3 times/week, for a total of 6 weeks.
Study NCT04892381 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: * Skin biopsy will be taken under local anesthesia :~* From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study.~* From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study:~  i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area~* The level of PD1 and PD-L1 will be detected using ELISA technique.~* The lesional biopsy will be assessed by routine hematoxylin and eosin (H\&E) to confirm the diagnosis of LP
Study NCT06361069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction cards, kaleidoscope and finger puppet
Description: A kaleidoscope, characterized by vibrant patterns visible through rotation of its cylinders, operates on the principle of light refraction, producing dynamic and ever-changing visual displays.~Distraction cards feature an array of images and shapes, each measuring approximately 5-8 cm in length. These intricate designs are discernible only upon careful examination of the cards.~Puppets, as a therapeutic intervention tool, significantly influence children's personal, social, and emotional development, facilitating their comfortable expression of emotions.
Study NCT05467397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]acetate
Description: Positron Emission Tomography (PET)
Study NCT04823221 — intervention group
Intervention type: DEVICE
Intervention: Rezūm System
Description: The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
Study NCT06418828 — intervention group
Intervention type: OTHER
Intervention: return to work
Description: Ask patients if they are going back to work
Study NCT04975438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 will be administered
Study NCT04975438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study NCT06577155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Regional anesthesia / analgesia
Study NCT06577155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine plus nalbuphine
Description: Regional anesthesia / analgesia
Study NCT05623878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-labeled NY108
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY108.
Study NCT04959877 — intervention group
Intervention type: BEHAVIORAL
Intervention: health education
Description: data collect / Telemedicine
Study NCT05464342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening LGI Carbohydrate Consumption Group
Description: Participants will receive in the evening food with low glycemic index
Study NCT05464342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening HGI Carbohydrate Consumption
Description: Participants will receive in the evening food with high glycemic index
Study NCT05464342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening NO-CHO Carbohydrate Consumption
Description: Participants will receive in the evening a meal with no carbohydrates at all.
Study NCT06044779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block using 0.25% Bupivacaine
Description: TAP block regional anesthesia with ultrasound guidance with administration of 20 mL of 0.25% Bupivacaine in the abdominal wall before the operation is completed. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
Study NCT06044779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block using 0.25% Bupivacaine
Description: Regional anesthesia ESP block under ultrasound guidance with 20 mL of 0.25% bupivacaine at the tip of the transverse process at the T9 level before completion of surgery. The patient was also fitted with a morphine PCA device with a background dose of 5 µg/kgBW/hour and a rescue dose of 1 mg with a lockout interval of 10 minutes.
Study NCT05862077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Hip Assist Robot(EX1)
Description: EX1 is a hip-type assist device developed by Samsung Electronics.
Study NCT05862077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program 1
Description: Exercise program 1 for fast walking by applying resistance and assist mode of EX1
Study NCT05862077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program 2
Description: Exercise program 2 for normal walking by applying resistance and assist mode of EX1
Study NCT05862077 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Without Wearable Hip Assist Robot(EX1)
Description: Overground walking without EX1
Study NCT04883008 — intervention group
Intervention type: DEVICE
Intervention: CorPath GRX with technIQ automated movements enabled (technIQ ON)
Description: The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be enabled and used at the discretion of the interventionalist.
Study NCT04883008 — intervention group
Intervention type: DEVICE
Intervention: CorPath GRX with technIQ automated movements disabled (technIQ OFF).
Description: The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.~TechnIQ automated movements are software-based automation of common maneuvers that interventionalists perform when manipulating catheters, guidewires, and devices by hand. In this group, automated movements will be disabled.
Study NCT04982146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelin
Description: 0.5mg per mL of total tumor volume calculated, administered percutaneously
Study NCT04634656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery
Study NCT04634656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
Study NCT05999968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT05999968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Administered orally.
Study NCT05999968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist/antagonist
Description: Physician's choice. Administered in accordance with the prescribing information.
Study NCT04845282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Graded Protein plus Resistance Training
Description: Participants will be counseled to consume the specific level of dietary protein plus the protein supplement is MusclePharm Combat 100% Whey. Specific values per week are listed below:~Week 1: 25 g of protein supplement (0.8 g protein/kg body weight) Week 2: 25 g of protein supplement (1.0 g protein/kg body weight) Week 3: 50 g of protein supplement (1.2 g protein/kg body weight) Week 4: 50 g of protein supplement (1.4 g protein/kg body weight) Week 5: 50 g of protein supplement (1.4 g protein/kg body weight) Week 6: 75 g of protein supplement (1.6 g protein/kg body weight) Week 7: 75 g of protein supplement (1.8 g protein/kg body weight) Week 8: 75 g of protein supplement (2.0 g protein/kg body weight) Week 9: 75 g of protein supplement (2.2 g protein/kg body weight) Week 10: 100 g of protein supplement (2.2 g protein/kg body weight)